Liza Cohen, MD
Ophthalmic Plastic and Reconstructive Surgery · Chicago, ILNPI 1134518087
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.3%), food and beverage and education — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Amgen at 56.4% of the total. Reporting peaked in 2021 at $2,266 and has fallen 83.9% since, to $366 in 2025.
Across 26 payments — averaging $182.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Stryker$736
- Alcon$558
- Biotissue Holdings Inc.$216
- AbbVie$150
- NEW World Medical,inc.$127
- plus $280 from 3 others
What the payments were for
- Speaking & faculty fees$2,10044%
- Food & beverage$1,90140%
- Education$73616%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 12 | $2,670 |
| Stryker | 2 | $736 |
| Alcon | 5 | $558 |
| Biotissue Holdings Inc. | 2 | $216 |
| AbbVie | 1 | $150 |
| NEW World Medical,inc. | 1 | $127 |
| Sun Pharmaceutical Industries Inc. | 1 | $114 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $109 |
| Genentech USA, Inc. | 1 | $57 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$2,540
- UNIVERSAL MANDIBLE$736
- Clareon$296
- AcrySof$243
- Tecnis IOL$218
- XEN GLAUCOMA TREATMENT SYSTEM$150
- Kahook Dual Blade$127
- Clearpath$127
- Ahmed Glaucoma Valve$127
- Streamline$127
- CEQUA$114
- VERITAS Vision System$109
- Tecnis Simplicity$109
How this compares
Too few ophthalmic plastic and reconstructive surgery providers in Illinoisto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 156 | $2,287 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 22 | $358 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Chicago
- Paul PhelpsChicago$141K
- Kenya WilliamsChicago$23K
- Hassan ShahChicago$1K
- Olivia ChengChicago$1K
- Sasha HubschmanChicago$406
- Tamara FountainDeerfield$1M
- Krishna PatelWheaton$4K
- Stephen WinklerDes Plaines$3K
- Jamie KeenHines$1K
- Duaa SharfiMerrionette Park$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.